Safety concerns associated with high-dose continuous infusion of cefepime among critically ill patients with mild renal impairment to augmented renal clearance at a level 1 trauma center: CEFTOX study
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01735-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Myriam Lamamri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Département d'Anesthésie Réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France. Hauptthemen laut MEDLINE: Cefepime, Anti-Bacterial Agents, Renal Insufficiency. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
High-dose continuous infusion of cefepime is frequently employed in ICU patients with a creatinine clearance above 60 mL/min. The CEFTOX study aimed to investigate whether this regimen could lead to cefepime overexposure and cefepime-induced neurotoxicity (CIN) in a cohort of severe trauma and brain-injured patients. This retrospective cohort study included patients from a Level 1 Trauma Center who received a continuous infusion of 6 g/day of cefepime and had a therapeutic drug monitoring (TDM) within 24–48 h of treatment initiation. They were divided into three groups based on creatinine clearance: mild renal impairment (60–90 mL/min), normal clearance (90–150 mL/min), and augmented renal clearance (ARC) (>150 mL/min). The primary outcome was cefepime overexposure. A key secondary outcome was CIN. One hundred and sixty-two critically ill patients were included: 84 with ARC, 62 with normal renal clearance, and 16 with mild renal impairment. Cefepime overexposure occurred in 72 (44.4%) patients. While 50% of patients with normal renal clearance experienced overexposure, the rate was higher in those with mild renal impairment (87.5%) and lower in those with ARC (32.1%; P < 0.0001). In the ARC group, age > 33 years was a risk factor for overexposure (odds ratio [OR] 3.76; 95% CI [1.30–10.95]; P = 0.01), while sepsis was a protective factor (OR 0.30; 95% CI [0.11–0.83]; P = 0.02). CIN was observed in 24% of overexposed patients when TDM results were obtained ≤48 h compared to 57.4% when results were delayed >48 h ( P = 0.006). These results highlight the need for early TDM and individualized dose adjustment to avoid CIN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département d'Anesthésie Réanimation, AP-HP, Hôpital Beaujon, DMU PARABOL, Clichy, France.
- NeuroDiderot, Neuroprotection of the Developing Brain, Université Paris Cité, INSERM UMR-S 1141, Paris, France.
- Centre de Recherche sur l'Inflammation, Inserm UMR_S 1149 et Université Paris Cité, Paris, France.
ORCID-Profile: Myriam Lamamri
Zitieren
APA
Lamamri, M., Rutman, C., Codorniu, A., Holleville, M., Sigaut, S., Weiss, E., & Jeantrelle, C. (2026). Safety concerns associated with high-dose continuous infusion of cefepime among critically ill patients with mild renal impairment to augmented renal clearance at a level 1 trauma center: CEFTOX study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01735-25
Vancouver
Lamamri M, Rutman C, Codorniu A, Holleville M, Sigaut S, Weiss E, et al. Safety concerns associated with high-dose continuous infusion of cefepime among critically ill patients with mild renal impairment to augmented renal clearance at a level 1 trauma center: CEFTOX study. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01735-25
BibTeX
@article{Lamamri2026,
author = {Lamamri, Myriam and Rutman, Charlotte and Codorniu, Anais and Holleville, Mathilde and Sigaut, Stéphanie and Weiss, Emmanuel and Jeantrelle, Caroline},
title = {Safety concerns associated with high-dose continuous infusion of cefepime among critically ill patients with mild renal impairment to augmented renal clearance at a level 1 trauma center: CEFTOX study},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01735-25}
}
EUVIMED